Douglas A. Plager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Douglas A. Plager has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Gerald J. Gleich
Department of Immunology
5 shared publicationsHirohito Kita
Allergic Diseases Research Laboratory, Mayo Clinic, Rochester, Minnesota, United States of America
3 shared publicationsCheryl R. Adolphson
Allergic Diseases Research Laboratory, Mayo Clinic and Foundation , Rochester, MN 55905
2 shared publicationsDavid A. Loegering
Department of Immunology, Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
2 shared publicationsDeborah A. Weiler
Department of Immunology, Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, 55905
2 shared publicationsJames L. Checkel
Allergic Diseases Research Laboratory, Mayo Clinic and Foundation , Rochester, MN 55905
2 shared publications
Latest Publications
- Open Access
- 6 July 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (7) , e11450
Gene Transcription Changes in Asthmatic Chronic Rhinosinusitis with Nasal Polyps and Comparison to Those in Atopic Dermatitis
Asthmatic chronic rhinosinusitis with nasal polyps (aCRSwNP) is a common disruptive eosinophilic disease without effective medical treatment. Therefore, we sought to identify gene expression changes, particularly those occurring early, in aCRSwNP. To highlight expression changes associated with eosinophilic epithelial inflammation, we further compared the changes in aCRSwNP with those in a second eosinophilic epithelial disease, atopic dermatitis (AD), which is also closely related to asthma. Genome-wide mRNA levels measured by exon array in both nasosinus inflamed mucosa and adjacent polyp from 11 aCRSwNP patients were compared to those in nasosinus tissue from 17 normal or rhinitis subjects without polyps. Differential expression of selected genes was confirmed by qRT-PCR or immunoassay, and transcription changes common to AD were identified. Comparison of aCRSwNP inflamed mucosa and polyp to normal/rhinitis tissue identified 447 differentially transcribed genes at ≥2 fold-change and adjusted p-value<0.05. These included increased transcription of chemokines localized to chromosome 17q11.2 (CCL13, CCL2, CCL8, and CCL11) that favor eosinophil and monocyte chemotaxis and chemokines (CCL18, CCL22, and CXCL13) that alternatively-activated monocyte-derived cells have been shown to produce. Additional transcription changes likely associated with Th2-like eosinophilic inflammation were prominent and included increased IL1RL1 (IL33 receptor) and EMR1&3 and decreased CRISP2&3. A down-regulated PDGFB-centric network involving several smooth muscle-associated genes was also implicated. Genes at 17q11.2, genes associated with alternative activation or smooth muscle, and the IL1RL1 gene were also differentially transcribed in AD. Our data implicate several genes or gene sets in aCRSwNP and eosinophilic epithelial inflammation, some that likely act in the earlier stages of inflammation. The identified gene expression changes provide additional diagnostic and therapeutic targets for aCRSwNP and other eosinophilic epithelial diseases.
- 6 July 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (7) , e11450
Open AccessGene Transcription Changes in Asthmatic Chronic Rhinosinusitis with Nasal Polyps and Comparison to Those in Atopic Dermatitis
Asthmatic chronic rhinosinusitis with nasal polyps (aCRSwNP) is a common disruptive eosinophilic disease without effective medical treatment. Therefore, we sought to identify gene expression changes, particularly those occurring early, in aCRSwNP. To highlight expression changes associated with eosinophilic epithelial inflammation, we further compared the changes in aCRSwNP with those in a second eosinophilic epithelial disease, atopic dermatitis (AD), which is also closely related to asthma. Genome-wide mRNA levels measured by exon array in both nasosinus inflamed mucosa and adjacent polyp from 11 aCRSwNP patients were compared to those in nasosinus tissue from 17 normal or rhinitis subjects without polyps. Differential expression of selected genes was confirmed by qRT-PCR or immunoassay, and transcription changes common to AD were identified. Comparison of aCRSwNP inflamed mucosa and polyp to normal/rhinitis tissue identified 447 differentially transcribed genes at ≥2 fold-change and adjusted p-value<0.05. These included increased transcription of chemokines localized to chromosome 17q11.2 (CCL13, CCL2, CCL8, and CCL11) that favor eosinophil and monocyte chemotaxis and chemokines (CCL18, CCL22, and CXCL13) that alternatively-activated monocyte-derived cells have been shown to produce. Additional transcription changes likely associated with Th2-like eosinophilic inflammation were prominent and included increased IL1RL1 (IL33 receptor) and EMR1&3 and decreased CRISP2&3. A down-regulated PDGFB-centric network involving several smooth muscle-associated genes was also implicated. Genes at 17q11.2, genes associated with alternative activation or smooth muscle, and the IL1RL1 gene were also differentially transcribed in AD. Our data implicate several genes or gene sets in aCRSwNP and eosinophilic epithelial inflammation, some that likely act in the earlier stages of inflammation. The identified gene expression changes provide additional diagnostic and therapeutic targets for aCRSwNP and other eosinophilic epithelial diseases.
- Open Access
- 15 September 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 183 (6) , 4013-4020
Eosinophil Ribonucleases and Their Cutaneous Lesion-Forming Activity
Eosinophil granule proteins are deposited in cutaneous lesions in many human diseases, but how these proteins contribute to pathophysiology is obscure. We injected eosinophil cationic protein (ECP or RNase 3), eosinophil-derived neurotoxin (EDN or RNase 2), eosinophil peroxidase (EPO), and major basic protein-1 (MBP1) intradermally into guinea pig and rabbit skin. ECP and EDN each induced distinct skin lesions at ≥2.5 μM that began at 2 days, peaking at ∼7 days and persisting up to 6 wk. These lesions were ulcerated (ECP) or crusted (EDN) with marked cellular infiltration. EPO and MBP1 (10 μM) each produced perceptible induration and erythema with moderate cellular infiltration resolving within 2 wk. ECP and EDN localized to dermal cells within 2 days, whereas EPO and MBP1 remained extracellular. Overall, cellular localization and RNase activity of ECP and EDN were critical for lesion formation; differential glycosylation, net cationic charge, or RNase activity alone did not account for lesion formation. Ulcerated lesions from patients with the hypereosinophilic syndrome showed ECP and EDN deposition comparable to that in guinea pig skin. In conclusion, ECP and EDN disrupt skin integrity and cause inflammation. Their presence in ulcerative skin lesions may explain certain findings in human eosinophil-associated diseases.
- 15 September 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 183 (6) , 4013-4020
Open AccessEosinophil Ribonucleases and Their Cutaneous Lesion-Forming Activity
Eosinophil granule proteins are deposited in cutaneous lesions in many human diseases, but how these proteins contribute to pathophysiology is obscure. We injected eosinophil cationic protein (ECP or RNase 3), eosinophil-derived neurotoxin (EDN or RNase 2), eosinophil peroxidase (EPO), and major basic protein-1 (MBP1) intradermally into guinea pig and rabbit skin. ECP and EDN each induced distinct skin lesions at ≥2.5 μM that began at 2 days, peaking at ∼7 days and persisting up to 6 wk. These lesions were ulcerated (ECP) or crusted (EDN) with marked cellular infiltration. EPO and MBP1 (10 μM) each produced perceptible induration and erythema with moderate cellular infiltration resolving within 2 wk. ECP and EDN localized to dermal cells within 2 days, whereas EPO and MBP1 remained extracellular. Overall, cellular localization and RNase activity of ECP and EDN were critical for lesion formation; differential glycosylation, net cationic charge, or RNase activity alone did not account for lesion formation. Ulcerated lesions from patients with the hypereosinophilic syndrome showed ECP and EDN deposition comparable to that in guinea pig skin. In conclusion, ECP and EDN disrupt skin integrity and cause inflammation. Their presence in ulcerative skin lesions may explain certain findings in human eosinophil-associated diseases.
- Open Access
- 6 January 2009
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 149 (2) , 119-126
Pimecrolimus Reduces Eosinophil Activation Associated with Calcium Mobilization
Background: Pimecrolimus is a calcineurin inhibitor that inhibits T cell and mast cell activation and effectively treats atopic dermatitis. However, its effects on eosinophils, a cell type implicated in allergic disease pathology, are unknown. Therefore, we examined the effects of pimecrolimus on eosinophil superoxide anion production, degranulation and survival. Methods: Purified eosinophils from normal or atopic donors were incubated with serial dilutions of pimecrolimus (μM to nM) and then stimulated with platelet activating factor (PAF), interleukin 5 (IL5), secretory immunoglobulin A (sIgA) or Alternaria alternata (Alt) fungus extract. Eosinophil activation was monitored by cytochrome c reduction resulting from superoxide anion production and by a 2-site immunoassay for eosinophil-derived neurotoxin (EDN) in cellular supernatants, as a marker of degranulation. Eosinophil survival was measured by propidium iodide exclusion using flow cytometry after 4 days in culture. Results: Normal and atopic eosinophil superoxide anion production induced by PAF, and associated with increased intracellular calcium, was inhibited up to 37% with 1 μM pimecrolimus. However, superoxide anion production induced by IL5 and sIgA was not consistently inhibited. EDN release, which ultimately depends on calcium, was inhibited about 30% with PAF, IL5 and sIgA stimulation for normal and atopic donor eosinophils. Furthermore, calcium-dependent Alt-induced EDN release was inhibited up to 49% with nanomolar pimecrolimus. Finally, increased eosinophil survival promoted by IL5 and sIgA was not influenced by pimecrolimus. Conclusion: Pimecrolimus moderately inhibits eosinophil superoxide anion production and EDN release associated with calcium mobilization, which may contribute to its efficacy in treating atopic dermatitis.
- 6 January 2009
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 149 (2) , 119-126
Open AccessPimecrolimus Reduces Eosinophil Activation Associated with Calcium Mobilization
Background: Pimecrolimus is a calcineurin inhibitor that inhibits T cell and mast cell activation and effectively treats atopic dermatitis. However, its effects on eosinophils, a cell type implicated in allergic disease pathology, are unknown. Therefore, we examined the effects of pimecrolimus on eosinophil superoxide anion production, degranulation and survival. Methods: Purified eosinophils from normal or atopic donors were incubated with serial dilutions of pimecrolimus (μM to nM) and then stimulated with platelet activating factor (PAF), interleukin 5 (IL5), secretory immunoglobulin A (sIgA) or Alternaria alternata (Alt) fungus extract. Eosinophil activation was monitored by cytochrome c reduction resulting from superoxide anion production and by a 2-site immunoassay for eosinophil-derived neurotoxin (EDN) in cellular supernatants, as a marker of degranulation. Eosinophil survival was measured by propidium iodide exclusion using flow cytometry after 4 days in culture. Results: Normal and atopic eosinophil superoxide anion production induced by PAF, and associated with increased intracellular calcium, was inhibited up to 37% with 1 μM pimecrolimus. However, superoxide anion production induced by IL5 and sIgA was not consistently inhibited. EDN release, which ultimately depends on calcium, was inhibited about 30% with PAF, IL5 and sIgA stimulation for normal and atopic donor eosinophils. Furthermore, calcium-dependent Alt-induced EDN release was inhibited up to 49% with nanomolar pimecrolimus. Finally, increased eosinophil survival promoted by IL5 and sIgA was not influenced by pimecrolimus. Conclusion: Pimecrolimus moderately inhibits eosinophil superoxide anion production and EDN release associated with calcium mobilization, which may contribute to its efficacy in treating atopic dermatitis.
- 23 December 2008
- Published by Wiley in Journal of Separation Science
- Vol. 32 (1) , 44-56
Extensive fractionation and identification of proteins within nasal lavage fluids from allergic rhinitis and asthmatic chronic rhinosinusitis patients
Allergic rhinitis (AR), chronic rhinosinusitis (CRS), and asthma are prevalent airway diseases that can have a substantial impact on a patient's quality of life. MS analyses of biological fluids can effectively screen for proteins associated with disease processes, however, initial detection of diagnostic proteins is difficult due to protein complexity and dynamic range. To enhance the detection of lower abundance proteins, intact nasal lavage fluid (NLF) proteins from nonpolypoid AR and from asthmatic CRS patients were extensively fractionated prior to LC/MS/MS analysis. Pooled NLF samples were processed to remove low molecular weight molecules and high abundance plasma proteins. Anion exchange (AX) chromatography followed by RP‐LC further separated the remaining intact NLF proteins. The resulting fractions were digested with trypsin and the peptides analyzed by LC/MS/MS. Spectra were searched with MASCOT, SEQUEST, and X!Tandem to obtain peptide identifications and subsequently analyzed by Scaffold software to identify parent proteins with at least 99% confidence. The 197 identified proteins are compared to those previously cited in the literature and the workflow evaluated to determine the usefulness for the detection of lower abundance proteins. This is the first extensive list of NLF proteins generated from CRS patients with coexisting asthma.
- 23 December 2008
- Published by Wiley in Journal of Separation Science
- Vol. 32 (1) , 44-56
Extensive fractionation and identification of proteins within nasal lavage fluids from allergic rhinitis and asthmatic chronic rhinosinusitis patients
Allergic rhinitis (AR), chronic rhinosinusitis (CRS), and asthma are prevalent airway diseases that can have a substantial impact on a patient's quality of life. MS analyses of biological fluids can effectively screen for proteins associated with disease processes, however, initial detection of diagnostic proteins is difficult due to protein complexity and dynamic range. To enhance the detection of lower abundance proteins, intact nasal lavage fluid (NLF) proteins from nonpolypoid AR and from asthmatic CRS patients were extensively fractionated prior to LC/MS/MS analysis. Pooled NLF samples were processed to remove low molecular weight molecules and high abundance plasma proteins. Anion exchange (AX) chromatography followed by RP‐LC further separated the remaining intact NLF proteins. The resulting fractions were digested with trypsin and the peptides analyzed by LC/MS/MS. Spectra were searched with MASCOT, SEQUEST, and X!Tandem to obtain peptide identifications and subsequently analyzed by Scaffold software to identify parent proteins with at least 99% confidence. The 197 identified proteins are compared to those previously cited in the literature and the workflow evaluated to determine the usefulness for the detection of lower abundance proteins. This is the first extensive list of NLF proteins generated from CRS patients with coexisting asthma.
- 17 November 2006
- Published by Wiley in Experimental Dermatology
- Vol. 16 (1) , 28-36
Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications
Abstract: Atopic dermatitis (AD) is a common pruritic dermatitis with macroscopically non‐lesional skin that is often abnormal. Therefore, we used high‐density oligonucleotide arrays to identify cutaneous gene transcription changes associated with early AD inflammation as potential disease control targets. Skin biopsy specimens analysed included normal skin from five healthy non‐atopic adults and both minimally lesional skin and nearby or contralateral non‐lesional skin from six adult AD patients. Data were analysed on an individual gene basis and to identify biologically relevant gene networks. Transcription levels of selected genes were also analysed by quantitative PCR. Differential transcription occurring early in AD skin was indicated for (i) individual genes such as C‐C chemokine ligand (CCL)18, CCL13, and interferon‐α2 (IFNα2), (ii) genes associated with peroxisome proliferator‐activated receptor (PPAR)α‐ and PPARγ‐regulated transcription, and possibly for (iii) immunoglobulin J‐chain and heavy chain isotype transcripts. These data suggest that local changes in immunoglobulin‐associated transcription may favour IgE over secretory immunoglobulin (multimeric IgM and IgA) expression in AD skin. Decreased PPAR activity appears common to both AD and psoriasis, and reduced cutaneous IFNα2 transcription also appears characteristic of AD. Identification of these genes and pathways will direct future research towards controlling AD.
- 17 November 2006
- Published by Wiley in Experimental Dermatology
- Vol. 16 (1) , 28-36
Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications
Abstract: Atopic dermatitis (AD) is a common pruritic dermatitis with macroscopically non‐lesional skin that is often abnormal. Therefore, we used high‐density oligonucleotide arrays to identify cutaneous gene transcription changes associated with early AD inflammation as potential disease control targets. Skin biopsy specimens analysed included normal skin from five healthy non‐atopic adults and both minimally lesional skin and nearby or contralateral non‐lesional skin from six adult AD patients. Data were analysed on an individual gene basis and to identify biologically relevant gene networks. Transcription levels of selected genes were also analysed by quantitative PCR. Differential transcription occurring early in AD skin was indicated for (i) individual genes such as C‐C chemokine ligand (CCL)18, CCL13, and interferon‐α2 (IFNα2), (ii) genes associated with peroxisome proliferator‐activated receptor (PPAR)α‐ and PPARγ‐regulated transcription, and possibly for (iii) immunoglobulin J‐chain and heavy chain isotype transcripts. These data suggest that local changes in immunoglobulin‐associated transcription may favour IgE over secretory immunoglobulin (multimeric IgM and IgA) expression in AD skin. Decreased PPAR activity appears common to both AD and psoriasis, and reduced cutaneous IFNα2 transcription also appears characteristic of AD. Identification of these genes and pathways will direct future research towards controlling AD.
- 15 November 2006
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (10) , 7340-7345
Major Basic Protein Homolog (MBP2): A Specific Human Eosinophil Marker
Human eosinophil granule major basic protein (MBP1) is an exceedingly basic (isoelectric point >11) 14-kDa protein, comprising the core of the secondary eosinophil granule. Recently, a less cationic homolog of MBP, termed MBPH or simply, MBP2, has been discovered. We prepared a panel of mAbs to MBP2 and used these Abs to localize and quantitate this molecule in leukocytes and biological fluids. Specific mAbs for MBP2 were selected using slot-blot analyses and used in a two-site immunoassay, Western blotting, and immunofluorescence microscopy. The sensitivity of the immunoassay was markedly improved by reduction and alkylation of MBP2. MBP1 is more abundant than MBP2 in lysates of eosinophils and their granules, as judged by immunoassay and Western blotting. By immunofluorescence, MBP1 is present in eosinophils, basophils, and a human mast cell line (HMC1), whereas MBP2 is only detected in eosinophils. Neither MBP1 nor MBP2 could be detected in any other peripheral blood leukocyte. MBP2 levels measured in plasma and serum were essentially identical. In contrast to past measurements for MBP1, MBP2 was not detected above normal levels in sera from pregnant donors. However, measurement of serum MBP2 discriminated patients with elevated eosinophils from normal subjects, and MBP2 was also detectable in other biological specimens, such as bronchoalveolar lavage, sputum, and stool. These results indicate that MBP2 is present only in eosinophils and that it may be a useful biomarker for eosinophil-associated diseases.
- 15 November 2006
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (10) , 7340-7345
Major Basic Protein Homolog (MBP2): A Specific Human Eosinophil Marker
Human eosinophil granule major basic protein (MBP1) is an exceedingly basic (isoelectric point >11) 14-kDa protein, comprising the core of the secondary eosinophil granule. Recently, a less cationic homolog of MBP, termed MBPH or simply, MBP2, has been discovered. We prepared a panel of mAbs to MBP2 and used these Abs to localize and quantitate this molecule in leukocytes and biological fluids. Specific mAbs for MBP2 were selected using slot-blot analyses and used in a two-site immunoassay, Western blotting, and immunofluorescence microscopy. The sensitivity of the immunoassay was markedly improved by reduction and alkylation of MBP2. MBP1 is more abundant than MBP2 in lysates of eosinophils and their granules, as judged by immunoassay and Western blotting. By immunofluorescence, MBP1 is present in eosinophils, basophils, and a human mast cell line (HMC1), whereas MBP2 is only detected in eosinophils. Neither MBP1 nor MBP2 could be detected in any other peripheral blood leukocyte. MBP2 levels measured in plasma and serum were essentially identical. In contrast to past measurements for MBP1, MBP2 was not detected above normal levels in sera from pregnant donors. However, measurement of serum MBP2 discriminated patients with elevated eosinophils from normal subjects, and MBP2 was also detectable in other biological specimens, such as bronchoalveolar lavage, sputum, and stool. These results indicate that MBP2 is present only in eosinophils and that it may be a useful biomarker for eosinophil-associated diseases.
- 1 February 2001
- Published by Wiley in Immunological Reviews
- Vol. 179 (1) , 192-202
A novel human homolog of eosinophil major basic protein
Summary: Eosinophil major basic protein (MBP) contributes to host defense and disease pathophysiology. Chromosome 11 contains the genes for human MBP1 (hMBP1) and a second novel MBP, hMBP2, in the centromere to 11q12 region. Interestingly, greater similarity exists between human and murine MBP1 and MBP2 orthologs, respectively, than between hMBP1 and hMBP2, suggesting a gene duplication event prior to the divergence of humans and mice. There is abundant mRNA for hMBP1 in both bone marrow (eosinophils and basophils) and placenta, but hMBP2 mRNA is present only in bone marrow (eosinophils). Comparison of proximal promoters for hMBP2, hMBP1, and murine MBP1 (mMBP1) shows a conserved GATA transcription factor binding site (functionally active in hMBP1). However, whether a C/EBP binding site common to hMBP1 and mMBP1 is functionally conserved in hMBP2 remains unresolved. Similarly, the role of conserved putative IK2 and STAT binding sites in MBP transcriptional control remains unknown. Like hMBP1, hMBP2 is in the eosinophil secondary granule. However, hMBP2 is twofold less positively charged than hMBP1 (+8 versus +16 at neutral pH), and this difference may explain hMBP2's similar, but often less potent, in vitro biological activities. Overall, while conservation of hMBP2's amino acid sequence (63% identity with hMBP1) suggests a common function(s) with hMBP1, hMBP2's substantially reduced charge and the existence of the similar mMBP2 argue for additional, unique functions for hMBP2.This work was supported in part by grants from the National Institutes of Health, AI 34577 and AI 09728 (GJG), and by the Mayo Foundation.
- 1 February 2001
- Published by Wiley in Immunological Reviews
- Vol. 179 (1) , 192-202
A novel human homolog of eosinophil major basic protein
Summary: Eosinophil major basic protein (MBP) contributes to host defense and disease pathophysiology. Chromosome 11 contains the genes for human MBP1 (hMBP1) and a second novel MBP, hMBP2, in the centromere to 11q12 region. Interestingly, greater similarity exists between human and murine MBP1 and MBP2 orthologs, respectively, than between hMBP1 and hMBP2, suggesting a gene duplication event prior to the divergence of humans and mice. There is abundant mRNA for hMBP1 in both bone marrow (eosinophils and basophils) and placenta, but hMBP2 mRNA is present only in bone marrow (eosinophils). Comparison of proximal promoters for hMBP2, hMBP1, and murine MBP1 (mMBP1) shows a conserved GATA transcription factor binding site (functionally active in hMBP1). However, whether a C/EBP binding site common to hMBP1 and mMBP1 is functionally conserved in hMBP2 remains unresolved. Similarly, the role of conserved putative IK2 and STAT binding sites in MBP transcriptional control remains unknown. Like hMBP1, hMBP2 is in the eosinophil secondary granule. However, hMBP2 is twofold less positively charged than hMBP1 (+8 versus +16 at neutral pH), and this difference may explain hMBP2's similar, but often less potent, in vitro biological activities. Overall, while conservation of hMBP2's amino acid sequence (63% identity with hMBP1) suggests a common function(s) with hMBP1, hMBP2's substantially reduced charge and the existence of the similar mMBP2 argue for additional, unique functions for hMBP2.This work was supported in part by grants from the National Institutes of Health, AI 34577 and AI 09728 (GJG), and by the Mayo Foundation.
- Open Access
- 1 May 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (20) , 14464-14473
A Novel and Highly Divergent Homolog of Human Eosinophil Granule Major Basic Protein
- 1 May 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (20) , 14464-14473
Open AccessA Novel and Highly Divergent Homolog of Human Eosinophil Granule Major Basic Protein